|
Market Closed -
Australian S.E.
08:10:10 19/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.2900 AUD | 0.00% |
|
0.00% | -55.38% |
| 10-07 | Gavin William Brown Nominates Candidates to the Board of Recce Pharmaceuticals | CI |
| 10-07 | Recce Pharmaceuticals Solicits Proxies from Shareholders | CI |
Company Valuation: Recce Pharmaceuticals Ltd
Data adjusted to current consolidation scope
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 158.1 | 111.4 | 122.4 | 83.63 | 117.1 | 88.67 | - |
| Change | - | -29.54% | 9.86% | -31.67% | 40.05% | -24.29% | - |
| Enterprise Value (EV) 1 | 158.1 | 113 | 126.8 | 73.18 | 114.4 | 113.6 | 40.57 |
| Change | - | -28.55% | 12.25% | -42.29% | 56.36% | -0.69% | -64.3% |
| P/E | -14.1x | -8.31x | -6.02x | -3.21x | -7.83x | -3.41x | 2.61x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | -0.4x | -0.2x | 0.34x | 0.2x | -0.1x | -0x |
| Capitalization / Revenue | - | 25.8x | 23.4x | 10.9x | 11.8x | 7.1x | 1.63x |
| EV / Revenue | - | 26.2x | 24.2x | 9.5x | 11.5x | 9.09x | 0.75x |
| EV / EBITDA | - | -8.83x | -7.69x | -3.69x | -8.8x | -5.17x | 1.13x |
| EV / EBIT | - | -8.9x | -7.53x | -3.63x | -8.6x | -5.09x | 1.13x |
| EV / FCF | - | -8.88x | -9.64x | -3.58x | -11.5x | -4.59x | 1.21x |
| FCF Yield | - | -11.3% | -10.4% | -28% | -8.7% | -21.8% | 82.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.0631 | -0.0752 | -0.0997 | -0.0904 | -0.0517 | -0.085 | 0.111 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | 4.311 | 5.236 | 7.705 | 9.939 | 12.5 | 54.3 |
| EBITDA 1 | - | -12.8 | -16.49 | -19.81 | -13 | -21.96 | 36 |
| EBIT 1 | - | -12.69 | -16.83 | -20.17 | -13.3 | -22.35 | 35.9 |
| Net income 1 | -10.99 | -13.08 | -17.66 | -21.43 | -14.96 | -25.1 | 33.4 |
| Net Debt 1 | - | 1.562 | 4.415 | -10.45 | -2.694 | 24.96 | -48.1 |
| Reference price 2 | 0.8900 | 0.6250 | 0.6000 | 0.2900 | 0.4050 | 0.2900 | 0.2900 |
| Nbr of stocks (in thousands) | 177,647 | 178,254 | 203,987 | 288,372 | 289,183 | 305,770 | - |
| Announcement Date | 8/31/22 A | 8/31/23 A | 8/30/24 A | 8/29/25 A | 8/31/26 A | - | - |
1AUD in Million2AUD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.41x | 9.09x | -5.17x | - | 61.7M | |
| 35.96x | 12.96x | 27.14x | 0.55% | 1,120B | |
| 37.4x | 6.3x | 17.74x | 2.09% | 616B | |
| 36.43x | 8.36x | 17.24x | 2.43% | 504B | |
| 20.46x | 4.99x | 12.38x | 2.64% | 367B | |
| 106.52x | 5.95x | 25.12x | 2.33% | 360B | |
| 21.18x | 5.54x | 13.63x | 2.88% | 288B | |
| 21.7x | 4.38x | 12.55x | 2.01% | 258B | |
| 27.46x | 7.06x | 12.64x | 2.33% | 234B | |
| -45.63x | 6.99x | 27.07x | 2.11% | 194B | |
| Average | 25.81x | 7.16x | 16.03x | 2.15% | 394.1B | |
| Weighted average by Cap. | 34.72x | 8.20x | 20.04x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- RCE Stock
- Valuation Recce Pharmaceuticals Ltd
Select your edition
All financial news and data tailored to specific country editions
